Market for B-cell non-Hodgkin's lymphoma will see slow growth over next 10 years - report

The treatment market for B-cell non-Hodgkin’s Lymphoma (NHL) is set to grow at a sluggish annual rate of one percent over the next decade hindered by the entry of biosimilars and generics during the forecast period, combined with a weak pipeline, according to a report by research and consulting firm GlobalData.

The research agency said the market is set to grow to $5.45 billion by 2024 $4.38 from billion in 2014. The latest report from GlobalData says the limited growth will be seen across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan.

Cai Xuan, GlobalData’s analyst covering oncology, said: “The launch of biosimilar rituximab across the 7MM in 2018 will have a significant negative impact on branded drug growth. Also significant will be the impact that generic bendamustine and lenalidomide will have on the treatment space as they are released at various intervals in each region during the forecast period. Furthermore, no late-stage drugs in the NHL pipeline are expected to achieve blockbuster status, as rituximab-based chemotherapy regimens are gold-standard therapies that dominate the NHL treatment algorithms across both indolent and aggressive forms of the disease.”